Mylan N.V. (MYL) Position Decreased by Hodges Capital Management Inc.
Hodges Capital Management Inc. lowered its stake in shares of Mylan N.V. (NASDAQ:MYL) by 64.8% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 136,440 shares of the company’s stock after selling 251,075 shares during the period. Hodges Capital Management Inc.’s holdings in Mylan N.V. were worth $5,297,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in MYL. BlackRock Inc. boosted its position in shares of Mylan N.V. by 3,447.5% in the first quarter. BlackRock Inc. now owns 38,822,643 shares of the company’s stock valued at $1,513,696,000 after buying an additional 37,728,274 shares during the last quarter. Pzena Investment Management LLC purchased a new position in shares of Mylan N.V. during the first quarter valued at about $283,158,000. TIAA CREF Investment Management LLC boosted its position in shares of Mylan N.V. by 187.3% in the first quarter. TIAA CREF Investment Management LLC now owns 4,315,668 shares of the company’s stock valued at $168,268,000 after buying an additional 2,813,653 shares during the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management purchased a new position in shares of Mylan N.V. during the second quarter valued at about $84,364,000. Finally, Morgan Stanley boosted its position in shares of Mylan N.V. by 82.6% in the first quarter. Morgan Stanley now owns 4,174,499 shares of the company’s stock valued at $162,765,000 after buying an additional 1,888,905 shares during the last quarter. 70.19% of the stock is currently owned by institutional investors.
Mylan N.V. (MYL) opened at 32.00 on Tuesday. The company has a market cap of $17.15 billion, a P/E ratio of 31.97 and a beta of 1.27. Mylan N.V. has a 1-year low of $31.47 and a 1-year high of $50.40. The stock has a 50 day moving average price of $38.42 and a 200 day moving average price of $39.28.
Mylan N.V. (NASDAQ:MYL) last issued its earnings results on Wednesday, May 10th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.01. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The firm had revenue of $2.72 billion for the quarter, compared to the consensus estimate of $2.81 billion. During the same quarter in the prior year, the business earned $0.76 earnings per share. The company’s revenue was up 24.1% compared to the same quarter last year. On average, equities research analysts anticipate that Mylan N.V. will post $5.12 EPS for the current fiscal year.
MYL has been the topic of several research reports. Wells Fargo & Company reissued a “market perform” rating and issued a $40.00 target price on shares of Mylan N.V. in a research report on Friday, April 14th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $46.00 target price (down from $48.00) on shares of Mylan N.V. in a research report on Monday, April 17th. Deutsche Bank AG dropped their target price on Mylan N.V. from $52.00 to $51.00 and set a “buy” rating on the stock in a research report on Tuesday, April 18th. BMO Capital Markets initiated coverage on Mylan N.V. in a research report on Monday, May 1st. They issued an “outperform” rating and a $50.00 target price on the stock. Finally, Zacks Investment Research cut Mylan N.V. from a “hold” rating to a “sell” rating in a research report on Monday, May 15th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $50.21.
In other news, President Rajiv Malik sold 25,000 shares of the company’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $1,000,000.00. Following the sale, the president now owns 799,855 shares in the company, valued at $31,994,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anthony Mauro sold 10,000 shares of the company’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider now owns 140,653 shares in the company, valued at approximately $5,626,120. The disclosure for this sale can be found here. 0.69% of the stock is owned by corporate insiders.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.